Skip to main content
Erschienen in: Journal of Thrombosis and Thrombolysis 1/2018

22.05.2018

Influence of tissue factor polymorphisms (603A>G and 5466A>G) on plasma tissue factor levels and their impact on deep vein thrombosis risk in young Indian population

verfasst von: Kamal Kishor, Amit Sharma, Kanwaljeet Singh, Ravi Ranjan, Hareram Pandey, Ravi Kumar, Vineet Kumar Kamal, Pravas Mishra, Manoranjan Mahapatra, Renu Saxena

Erschienen in: Journal of Thrombosis and Thrombolysis | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

Deep vein thrombosis (DVT) is multifactorial disorder and well known to cause substantial morbidity and mortality. There is sparse data in the Asian population, particularly India regarding association of tissue factor (TF) gene single nucleotide polymorphisms (SNPs) with plasma TF levels in DVT. So, we analyzed the distribution of SNPs (603A>G and 5466A>G) in India, to evaluate their effect on TF levels in DVT patients. Plasma level and SNPs (603A>G and 5466A>G) of TF gene were screened in subjects (100 DVT patients and 100 controls). Patients had significantly higher TF levels than controls (patients: 84.95 ± 17.16 pg/ml, controls: 70.55 ± 15.87 pg/ml, p < 0.001). G allele of 603A>G polymorphism was significantly higher in patients than controls (patients: 40.5% controls: 27.5%, p = 0.004). Subjects with AG and GG genotype had significantly higher TF levels than AA genotype (p = 0.001). After multiple logistic regression analysis, risk of DVT was increased 1.398 fold (95% CI 0.738–2.651) and 4.41 fold (95% CI 1.404–13.884) with AG and GG genotype respectively. Allelic and genotypic frequencies of 5466A>G polymorphism was neither associated with TF levels nor with DVT. We found high TF level in patients with TF 603A>G polymorphism, which is an important predisposing factor in increasing risk of DVT in young Indians. Furthermore, GG genotype of 603A>G polymorphism augments the risk of thrombosis by 4.4 fold, thus highlighting the significance of this polymorphism in the development of DVT. So, we suggest that inclusion of 603A>G polymorphism in prothrombotic work-up may be helpful in making the treatment strategy in DVT patients.
Literatur
2.
Zurück zum Zitat Malone PC, Agutter PS (2006) The aetiology of deep venous thrombosis. Q J Med 99:581–593CrossRef Malone PC, Agutter PS (2006) The aetiology of deep venous thrombosis. Q J Med 99:581–593CrossRef
3.
Zurück zum Zitat Carter CJ (1994) The natural history and epidemiology of venous thrombosis. Prog Cardiovasc Dis 36:423–438CrossRefPubMed Carter CJ (1994) The natural history and epidemiology of venous thrombosis. Prog Cardiovasc Dis 36:423–438CrossRefPubMed
4.
Zurück zum Zitat Franco RF, Reitsma PH (2001) Genetic risk factors of venous thrombosis. Hum Genet 109(4):369–384CrossRefPubMed Franco RF, Reitsma PH (2001) Genetic risk factors of venous thrombosis. Hum Genet 109(4):369–384CrossRefPubMed
5.
Zurück zum Zitat Poort SR, Rosendaal FR, Reitsma PH, Bertina RM (1996) A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 88(10):3698–3703PubMed Poort SR, Rosendaal FR, Reitsma PH, Bertina RM (1996) A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 88(10):3698–3703PubMed
6.
Zurück zum Zitat Bertina RM (1997) Factor V Leiden and other coagulation factor mutations affecting thrombotic risk. Clin Chem 43(9):1678–1683PubMed Bertina RM (1997) Factor V Leiden and other coagulation factor mutations affecting thrombotic risk. Clin Chem 43(9):1678–1683PubMed
7.
Zurück zum Zitat Sambola A, Osende J, Hathcock J, Degen M, Nemerson Y, Fuster V, Crandall J, Badimon JJ (2003) Role of risk factors in the modulation of tissue factor activity and blood thrombogenicity. Circulation 107(7):973–977CrossRefPubMed Sambola A, Osende J, Hathcock J, Degen M, Nemerson Y, Fuster V, Crandall J, Badimon JJ (2003) Role of risk factors in the modulation of tissue factor activity and blood thrombogenicity. Circulation 107(7):973–977CrossRefPubMed
8.
Zurück zum Zitat Mackman N (2004) Role of tissue factor in hemostasis, thrombosis, and vascular development. Arterioscler Thromb Vasc Biol 24(6):1015–1022CrossRefPubMed Mackman N (2004) Role of tissue factor in hemostasis, thrombosis, and vascular development. Arterioscler Thromb Vasc Biol 24(6):1015–1022CrossRefPubMed
9.
Zurück zum Zitat Kamikura Y, Wada H, Nobori T, Kobayashi T, Sase T, Nishikawa M, Ishikura K, Yamada N, Abe Y, Nishioka J, Nakano T, Shiku H (2005) Elevated levels of leukocyte tissue factor mRNA in patients with venous thromboembolism. Thromb Res 116(4):307–312CrossRefPubMed Kamikura Y, Wada H, Nobori T, Kobayashi T, Sase T, Nishikawa M, Ishikura K, Yamada N, Abe Y, Nishioka J, Nakano T, Shiku H (2005) Elevated levels of leukocyte tissue factor mRNA in patients with venous thromboembolism. Thromb Res 116(4):307–312CrossRefPubMed
10.
Zurück zum Zitat Kim HK, Song KS, Park YS, Yun Y, Shim WH (2000) Changes of plasma tissue factor and tissue factor pathway inhibitor antigen levels and induction of tissue factor expression on the monocytes in coronary artery disease. Cardiology 93:31–36CrossRefPubMed Kim HK, Song KS, Park YS, Yun Y, Shim WH (2000) Changes of plasma tissue factor and tissue factor pathway inhibitor antigen levels and induction of tissue factor expression on the monocytes in coronary artery disease. Cardiology 93:31–36CrossRefPubMed
11.
Zurück zum Zitat Falciani M, Gori AM, Fedi S, Chiarugi L, Simonetti I, Dabizzi RP, Prisco D, Pepe G, Abbate R, Gensini GF, Neri Serneri GG (1998) Elevated tissue factor and tissue factor pathway inhibitor circulating levels in ischaemic heart disease patients. Thromb Haemost 79(3):495–499CrossRefPubMed Falciani M, Gori AM, Fedi S, Chiarugi L, Simonetti I, Dabizzi RP, Prisco D, Pepe G, Abbate R, Gensini GF, Neri Serneri GG (1998) Elevated tissue factor and tissue factor pathway inhibitor circulating levels in ischaemic heart disease patients. Thromb Haemost 79(3):495–499CrossRefPubMed
12.
Zurück zum Zitat Freeburn JC, Wallace JM, Strain JJ, Sinnamon DG, Craig BM, Johnson D, Gilmore WS (1998) Monocyte tissue factor-like activity in post myocardial infarction patients. Br J Haematol 102(2):605–608CrossRefPubMed Freeburn JC, Wallace JM, Strain JJ, Sinnamon DG, Craig BM, Johnson D, Gilmore WS (1998) Monocyte tissue factor-like activity in post myocardial infarction patients. Br J Haematol 102(2):605–608CrossRefPubMed
13.
14.
Zurück zum Zitat Morange PE, Blankenberg S, Alessi MC, Bickel C, Rupprecht HJ, Schnabel R, Lubos E, Münzel T, Peetz D, Nicaud V, Juhan-Vague I, Tiret L (2007) Prognostic value of plasma tissue factor and tissue factor pathway inhibitor for cardiovascular death in patients with coronary artery disease: the AtheroGene study. J Thromb Haemost 5(3):475–482CrossRefPubMed Morange PE, Blankenberg S, Alessi MC, Bickel C, Rupprecht HJ, Schnabel R, Lubos E, Münzel T, Peetz D, Nicaud V, Juhan-Vague I, Tiret L (2007) Prognostic value of plasma tissue factor and tissue factor pathway inhibitor for cardiovascular death in patients with coronary artery disease: the AtheroGene study. J Thromb Haemost 5(3):475–482CrossRefPubMed
15.
Zurück zum Zitat Seljeflot I, Hurlen M, Hole T, Arnesen H (2003) Soluble tissue factor as predictor of future events in patients with acute myocardial infarction. Thromb Res 111(6):369–372CrossRefPubMed Seljeflot I, Hurlen M, Hole T, Arnesen H (2003) Soluble tissue factor as predictor of future events in patients with acute myocardial infarction. Thromb Res 111(6):369–372CrossRefPubMed
16.
Zurück zum Zitat Kwon A, Jo SH, Jo YA, Park JY, Kim M, Kang HJ, Kim HS, Cho HC, Lee YK (2014) Genetic polymorphisms and plasma levels of tissue factor and tissue factor pathway inhibitor in venous thromboembolism. Blood Coagul Fibrinolysis 25(5):416–421CrossRefPubMed Kwon A, Jo SH, Jo YA, Park JY, Kim M, Kang HJ, Kim HS, Cho HC, Lee YK (2014) Genetic polymorphisms and plasma levels of tissue factor and tissue factor pathway inhibitor in venous thromboembolism. Blood Coagul Fibrinolysis 25(5):416–421CrossRefPubMed
17.
Zurück zum Zitat Ott I, Koch W, von Beckerath N, de Waha R, Malawaniec A, Mehilli J, Schömig A, Kastrati A (2004) Tissue factor promoter polymorphism-603 A/G is associated with myocardial infarction. Atherosclerosis 177(1):189–191CrossRefPubMed Ott I, Koch W, von Beckerath N, de Waha R, Malawaniec A, Mehilli J, Schömig A, Kastrati A (2004) Tissue factor promoter polymorphism-603 A/G is associated with myocardial infarction. Atherosclerosis 177(1):189–191CrossRefPubMed
19.
Zurück zum Zitat Mälarstig A, Tenno T, Johnston N, Lagerqvist B, Axelsson T, Syvänen AC, Wallentin L, Siegbahn A (2005) Genetic variations in the tissue factor gene are associated with clinical outcome in acute coronary syndrome and expression levels in human monocytes. Arterioscler Thromb Vasc Biol 25(12):2667–2672CrossRefPubMed Mälarstig A, Tenno T, Johnston N, Lagerqvist B, Axelsson T, Syvänen AC, Wallentin L, Siegbahn A (2005) Genetic variations in the tissue factor gene are associated with clinical outcome in acute coronary syndrome and expression levels in human monocytes. Arterioscler Thromb Vasc Biol 25(12):2667–2672CrossRefPubMed
20.
Zurück zum Zitat Soejima H, Ogawa H, Yasue H, Kaikita K, Nishiyama K, Misumi K, Takazoe K, Miyao Y, Yoshimura M, Kugiyama K, Nakamura S, Tsuji I, Kumeda K (1999) Heightened tissue factor associated with tissue factor pathway inhibitor and prognosis in patients with unstable angina. Circulation 99(22):2908–2913CrossRefPubMed Soejima H, Ogawa H, Yasue H, Kaikita K, Nishiyama K, Misumi K, Takazoe K, Miyao Y, Yoshimura M, Kugiyama K, Nakamura S, Tsuji I, Kumeda K (1999) Heightened tissue factor associated with tissue factor pathway inhibitor and prognosis in patients with unstable angina. Circulation 99(22):2908–2913CrossRefPubMed
21.
Zurück zum Zitat El-Hagracy RS, Kamal GM, Sabry IM, Saad AA, Abou El Ezz NF, Nasr HA (2010) Tissue Factor, tissue factor pathway inhibitor and factor VII activity in cardiovascular complicated type 2 diabetes mellitus. Oman Med J 25(3):173–178CrossRefPubMedPubMedCentral El-Hagracy RS, Kamal GM, Sabry IM, Saad AA, Abou El Ezz NF, Nasr HA (2010) Tissue Factor, tissue factor pathway inhibitor and factor VII activity in cardiovascular complicated type 2 diabetes mellitus. Oman Med J 25(3):173–178CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Arnaud E, Barbalat V, Nicaud V, Cambien F, Evans A, Morrison C, Arveiler D, Luc G, Ruidavets JB, Emmerich J, Fiessinger JN, Aiach M (2000) Polymorphisms in the 5′ regulatory region of the tissue factor gene and the risk of myocardial infarction and venous thromboembolism: the ECTIM and PATHROS studies. Etude Cas-Temoins de l_Infarctus du Myocarde. Paris Thrombosis case–control Study. Arterioscler Thromb Vasc Biol 20(3):892–898CrossRefPubMed Arnaud E, Barbalat V, Nicaud V, Cambien F, Evans A, Morrison C, Arveiler D, Luc G, Ruidavets JB, Emmerich J, Fiessinger JN, Aiach M (2000) Polymorphisms in the 5′ regulatory region of the tissue factor gene and the risk of myocardial infarction and venous thromboembolism: the ECTIM and PATHROS studies. Etude Cas-Temoins de l_Infarctus du Myocarde. Paris Thrombosis case–control Study. Arterioscler Thromb Vasc Biol 20(3):892–898CrossRefPubMed
23.
Zurück zum Zitat Eroğlu A, Ceylan GG, Ozturk E, Yalcin A, Yalcin B, Karasoy D (2016) The efficacy of tissue factor − 603A/G and + 5466A> G polymorphisms at the development of venous thrombo embolism in cancer patients. Exp Oncol 8(3):187–190 Eroğlu A, Ceylan GG, Ozturk E, Yalcin A, Yalcin B, Karasoy D (2016) The efficacy of tissue factor − 603A/G and + 5466A> G polymorphisms at the development of venous thrombo embolism in cancer patients. Exp Oncol 8(3):187–190
24.
Zurück zum Zitat Campo G, Valgimigli M, Ferraresi P, Malagutti P, Baroni M, Arcozzi C, Gemmati D, Percoco G, Parrinello G, Ferrari R, Bernardi F (2006) Tissue factor and coagulation factor VII levels during acute myocardial infarction: association with genotype and adverse events. Arterioscler Thromb Vasc Biol 26:2800–2806CrossRefPubMed Campo G, Valgimigli M, Ferraresi P, Malagutti P, Baroni M, Arcozzi C, Gemmati D, Percoco G, Parrinello G, Ferrari R, Bernardi F (2006) Tissue factor and coagulation factor VII levels during acute myocardial infarction: association with genotype and adverse events. Arterioscler Thromb Vasc Biol 26:2800–2806CrossRefPubMed
Metadaten
Titel
Influence of tissue factor polymorphisms (603A>G and 5466A>G) on plasma tissue factor levels and their impact on deep vein thrombosis risk in young Indian population
verfasst von
Kamal Kishor
Amit Sharma
Kanwaljeet Singh
Ravi Ranjan
Hareram Pandey
Ravi Kumar
Vineet Kumar Kamal
Pravas Mishra
Manoranjan Mahapatra
Renu Saxena
Publikationsdatum
22.05.2018
Verlag
Springer US
Erschienen in
Journal of Thrombosis and Thrombolysis / Ausgabe 1/2018
Print ISSN: 0929-5305
Elektronische ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-018-1666-6

Weitere Artikel der Ausgabe 1/2018

Journal of Thrombosis and Thrombolysis 1/2018 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.